Aug 2026· Virus Research· Vol 371, pp. 199782· 0 citations· 60 references
Medicine
TL;DR
In vivo models confirm significant reduction of resistant pathogens, supporting clinical translational potential and key challenges remain in off-target effects, manufacturing, and regulatory approval for human use.
Abstract
Highlights • CRISPR-Cas systems enable programmable, sequence-specific elimination of antimicrobial resistance genes.• Diverse Cas effectors (Cas9, Cas3, Cas12a, Cas13, Cas14) and delivery platforms (phages, plasmids, nanoparticles, OMVs) expand therapeutic versatility.• CRISPRi offers reversible resistance suppression, while AI-guided design and toxin-antitoxin systems enhance efficacy and safety.• In vivo models confirm significant reduction of resistant pathogens, supporting clinical translational potential.• Key challenges remain in off-target effects, manufacturing, and regulatory approval for human use.
CRISPR-Cas systems in prokaryotes serve as adaptive immune systems that neutralize phage infections through RNA-guided nucleases. Immunization is achieved during the adaptation stage through Cas1-Cas2 integrase-mediated insertion of short foreign DNA snippets, termed spacers, into a CRISPR array in the host genome. Thi...
Ugne Gaizauskaite, I. Songailienė, G. Sasnauskas et al.· TIBS -Trends in Biochemical...· 0 citations
This review critically examines bacteriophage-based antimicrobials, CRISPR-Cas therapeutic systems, and their emerging integration as CRISPR-armed phages, highlighting their comparative advantages, current limitations, and future potential as promising targeted antimicrobial approach platforms requiring further clinica...
Anjaneyulu Musini, V. Yata, Sarad Pawar Naik Bukke et al.· Molecular Biology Reports· 0 citations
This review critically evaluates CRISPR's role in RNA editing, emphasizing its importance for functional genomics and development of recombinant vaccines, andTranslational challenges are critically discussed, including off-target effects, delivery limitations, and ethical issues.
Mahmood Ul Hasan, M. Azhar, Noor-Ul-Saba et al.· Journal of Virological Metho...· 0 citations
Immunogenicity of CRISPR-associated nucleases (Cas) is a critical barrier to the development of safe and effective genome editing therapies. These proteins inherently pose a risk of immune recognition due to their prokaryotic origins. A multitude of factors, such as the delivery vehicle, the route of administration, co...
Bryan Hu, Venkata Sumanth Reddy Gutty, Roland W. Herzog et al.· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
